Real-time Estimate
Cboe BZX
10:16:38 2024-05-23 am EDT
|
5-day change
|
1st Jan Change
|
8.395
USD
|
-1.58%
|
|
+6.38%
|
-38.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,373
|
522.2
|
411.3
|
244.2
|
517.3
|
331.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,373
|
423.1
|
259.8
|
127.5
|
442
|
295.4
|
333.9
|
341
|
P/E ratio
|
-2,376
x
|
-8.44
x
|
-10.2
x
|
-6.15
x
|
-9.41
x
|
-4.89
x
|
-11
x
|
-593
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
26.5
x
|
10.2
x
|
4.82
x
|
6.75
x
|
2.92
x
|
2.1
x
|
1.64
x
|
EV / Revenue
|
80.7
x
|
21.5
x
|
6.45
x
|
2.52
x
|
5.77
x
|
2.6
x
|
2.12
x
|
1.69
x
|
EV / EBITDA
|
-42.9
x
|
-11.9
x
|
-9.35
x
|
-3.33
x
|
-6.88
x
|
-4.77
x
|
-15.5
x
|
39
x
|
EV / FCF
|
-46.9
x
|
-13.1
x
|
-7.03
x
|
-4.44
x
|
-7.34
x
|
-5.52
x
|
-19.2
x
|
21.7
x
|
FCF Yield
|
-2.13%
|
-7.62%
|
-14.2%
|
-22.5%
|
-13.6%
|
-18.1%
|
-5.21%
|
4.61%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
17
x
|
38.1
x
|
9.96
x
|
Nbr of stocks (in thousands)
|
21,175
|
21,625
|
24,926
|
25,208
|
25,676
|
25,810
|
-
|
-
|
Reference price
2 |
64.86
|
24.15
|
16.50
|
9.687
|
20.15
|
12.85
|
12.85
|
12.85
|
Announcement Date
|
8/29/19
|
8/27/20
|
8/26/21
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.03
|
19.71
|
40.31
|
50.63
|
76.65
|
113.5
|
157.7
|
201.8
|
EBITDA
1 |
-32
|
-35.56
|
-27.8
|
-38.31
|
-64.24
|
-61.9
|
-21.48
|
8.734
|
EBIT
1 |
-34.75
|
-58.99
|
-36.6
|
-40.46
|
-65.2
|
-66.05
|
-32.05
|
-3.546
|
Operating Margin
|
-204.07%
|
-299.23%
|
-90.79%
|
-79.91%
|
-85.07%
|
-58.17%
|
-20.32%
|
-1.76%
|
Earnings before Tax (EBT)
1 |
-34.78
|
-58.09
|
-36.6
|
-39.17
|
-53.98
|
-66.2
|
-29.41
|
-0.4814
|
Net income
1 |
-34.6
|
-58.09
|
-36.66
|
-39.22
|
-54.08
|
-67.8
|
-32.83
|
-4.639
|
Net margin
|
-203.24%
|
-294.68%
|
-90.94%
|
-77.47%
|
-70.56%
|
-59.71%
|
-20.82%
|
-2.3%
|
EPS
2 |
-0.0273
|
-2.861
|
-1.613
|
-1.574
|
-2.140
|
-2.629
|
-1.171
|
-0.0217
|
Free Cash Flow
1 |
-29.28
|
-32.26
|
-36.95
|
-28.75
|
-60.21
|
-53.54
|
-17.39
|
15.72
|
FCF margin
|
-171.97%
|
-163.62%
|
-91.66%
|
-56.77%
|
-78.56%
|
-47.15%
|
-11.02%
|
7.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
180.03%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/19
|
8/27/20
|
8/26/21
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
10.2
|
13.53
|
10.72
|
14.21
|
10.98
|
11.71
|
13.82
|
13.91
|
15.76
|
17.92
|
21.25
|
21.7
|
16.81
|
22.22
|
33.88
|
42.97
|
29.58
|
35.4
|
EBITDA
1 |
-17.48
|
-15.65
|
-38.43
|
-4.299
|
-13.53
|
-8.594
|
-8.271
|
-7.639
|
-13.52
|
-16.8
|
-14.24
|
-18.47
|
-
|
-17.26
|
-10.14
|
-5.752
|
-9.536
|
-6.358
|
EBIT
1 |
-19.18
|
-20.98
|
-39.29
|
-6.486
|
-13.81
|
-8.94
|
-8.739
|
-8.691
|
-14.81
|
-17.03
|
-14.49
|
-18.76
|
-26.04
|
-20.97
|
-12.93
|
-9.376
|
-19.25
|
-17.57
|
Operating Margin
|
-187.97%
|
-155.07%
|
-366.64%
|
-45.65%
|
-125.84%
|
-76.33%
|
-63.22%
|
-62.49%
|
-93.94%
|
-95%
|
-68.2%
|
-86.46%
|
-154.95%
|
-94.34%
|
-38.17%
|
-21.82%
|
-65.09%
|
-49.64%
|
Earnings before Tax (EBT)
1 |
-19.2
|
-
|
-38.64
|
-6.496
|
-13.77
|
-8.792
|
-8.49
|
-7.839
|
-13.73
|
-15.81
|
-13.55
|
-10.78
|
-28.2
|
-20.17
|
-12.76
|
-8.733
|
-18.87
|
-17.19
|
Net income
1 |
-20.4
|
-31.31
|
-38.65
|
-6.506
|
-13.78
|
-8.798
|
-8.496
|
-7.874
|
-13.77
|
-15.83
|
-13.57
|
-10.8
|
-28.24
|
-20.18
|
-12.77
|
-8.769
|
-18.92
|
-17.24
|
Net margin
|
-199.9%
|
-231.42%
|
-360.61%
|
-45.79%
|
-125.52%
|
-75.12%
|
-61.46%
|
-56.62%
|
-87.39%
|
-88.35%
|
-63.85%
|
-49.77%
|
-168.03%
|
-90.8%
|
-37.68%
|
-20.41%
|
-63.97%
|
-48.71%
|
EPS
2 |
-0.0114
|
-
|
-1.811
|
-0.2620
|
-0.5533
|
-0.3513
|
-0.3345
|
-0.3089
|
-0.5527
|
-0.6252
|
-0.5295
|
-0.4280
|
-1.105
|
-0.7824
|
-0.4953
|
-0.3375
|
-0.7265
|
-0.6585
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/19
|
1/31/20
|
8/27/20
|
8/26/21
|
5/12/22
|
8/11/22
|
11/10/22
|
2/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
2/22/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
2.3
|
9.43
|
Net Cash position
1 |
-
|
99.1
|
151
|
117
|
75.3
|
36.2
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.1068
x
|
1.079
x
|
Free Cash Flow
1 |
-29.3
|
-32.3
|
-36.9
|
-28.7
|
-60.2
|
-53.5
|
-17.4
|
15.7
|
ROE (net income / shareholders' equity)
|
-140%
|
-90.2%
|
-28.3%
|
-28.2%
|
-52.9%
|
-148%
|
-48%
|
64.2%
|
ROA (Net income/ Total Assets)
|
-
|
-77.7%
|
-25.6%
|
-24.9%
|
-33.7%
|
-40.6%
|
-23.9%
|
9.78%
|
Assets
1 |
-
|
74.81
|
143.4
|
157.6
|
160.4
|
167.1
|
137.3
|
-47.44
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.7600
|
0.3400
|
1.290
|
Cash Flow per Share
2 |
-
|
-
|
-1.580
|
-1.120
|
-2.290
|
-1.070
|
-0.8400
|
-
|
Capex
1 |
1.47
|
0.82
|
1.23
|
0.66
|
2.11
|
1.57
|
1.77
|
2.09
|
Capex / Sales
|
8.66%
|
4.14%
|
3.06%
|
1.31%
|
2.75%
|
1.38%
|
1.12%
|
1.04%
|
Announcement Date
|
8/29/19
|
8/27/20
|
8/26/21
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
12.85
AUD Average target price
35
AUD Spread / Average Target +172.42% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.59% | 220M | | +60.88% | 62.59B | | -2.21% | 41.18B | | +44.42% | 40.29B | | -8.29% | 27.9B | | +12.76% | 26.21B | | -21.42% | 19.09B | | +5.65% | 13.08B | | +24.57% | 12.26B | | +28.12% | 12.05B |
Other Biotechnology & Medical Research
|